PDF(Pubmed)
Abstract：
UNASSIGNED: Nail psoriasis remains a challenging condition with limited satisfaction from current treatments. An increasing number of neuropeptides were reported in psoriatic tissue.
UNASSIGNED: To compare the efficacy of botulinum toxin A (BoNT-A) injection, triamcinolone acetonide (TA) injection, topical combination of vitamin D/steroid (VitD/steroid) and placebo in improving nail psoriasis.
UNASSIGNED: A 24-week randomized intraindividual comparative-controlled study involved participants with at least 4 psoriatic fingernails, each with a total target nail psoriasis severity index (NAPSI) score of at least 3 points. Nails were randomly received different treatments; intralesional BoNT-A injection at baseline, intralesional TA at baseline and eighth week, daily topical VitD/steroid application for 16 weeks and placebo.
UNASSIGNED: Evaluation of 64 psoriatic fingernails showed a 40% reduction in the total target NAPSI score at 24 weeks following BoNT-A injection (P = .001). BoNT-A significantly improved nail bed lesions more than TA and topical VitD/steroid (P = .038), with no reported serious adverse effects.
UNASSIGNED: Relatively small sample size; hand hygiene during the COVID-19 pandemic may interfere NAPSI score evaluation.
UNASSIGNED: BoNT-A injection emerges as a promising and effective therapy for nail psoriasis, providing sustained efficacy lasting up to 6 months with a single injection.
UNASSIGNED: To compare the efficacy of botulinum toxin A (BoNT-A) injection, triamcinolone acetonide (TA) injection, topical combination of vitamin D/steroid (VitD/steroid) and placebo in improving nail psoriasis.
UNASSIGNED: A 24-week randomized intraindividual comparative-controlled study involved participants with at least 4 psoriatic fingernails, each with a total target nail psoriasis severity index (NAPSI) score of at least 3 points. Nails were randomly received different treatments; intralesional BoNT-A injection at baseline, intralesional TA at baseline and eighth week, daily topical VitD/steroid application for 16 weeks and placebo.
UNASSIGNED: Evaluation of 64 psoriatic fingernails showed a 40% reduction in the total target NAPSI score at 24 weeks following BoNT-A injection (P = .001). BoNT-A significantly improved nail bed lesions more than TA and topical VitD/steroid (P = .038), with no reported serious adverse effects.
UNASSIGNED: Relatively small sample size; hand hygiene during the COVID-19 pandemic may interfere NAPSI score evaluation.
UNASSIGNED: BoNT-A injection emerges as a promising and effective therapy for nail psoriasis, providing sustained efficacy lasting up to 6 months with a single injection.
摘要：
■指甲牛皮癣仍然是一种具有挑战性的疾病，对当前治疗的满意度有限。据报道，牛皮癣组织中神经肽的数量有所增加。
■为了比较肉毒杆菌毒素A（BoNT-A）注射液的疗效，曲安奈德(TA)注射液,维生素D/类固醇（VitD/类固醇）和安慰剂的局部组合在改善指甲牛皮癣。
一项为期24周的随机个人比较对照研究，参与者至少有4个牛皮癣指甲，每个人的总目标指甲牛皮癣严重程度指数（NAPSI）评分至少3分。钉子随机接受不同的治疗；基线时病灶内注射BoNT-A，在基线和第八周的病灶内TA，每日局部VitD/类固醇应用16周和安慰剂。
■对64个牛皮癣指甲的评估显示，在注射BoNT-A后24周时，总目标NAPSI评分降低了40％（P=.001）。与TA和局部VitD/类固醇相比，BoNT-A显着改善了甲床病变（P=0.038），没有报告的严重不良反应。
■样本量相对较小；COVID-19大流行期间的手部卫生可能会干扰NAPSI评分评估。
■BoNT-A注射液是治疗指甲牛皮癣的一种有前途且有效的疗法，提供持续的疗效持续长达6个月与单次注射。
■为了比较肉毒杆菌毒素A（BoNT-A）注射液的疗效，曲安奈德(TA)注射液,维生素D/类固醇（VitD/类固醇）和安慰剂的局部组合在改善指甲牛皮癣。
一项为期24周的随机个人比较对照研究，参与者至少有4个牛皮癣指甲，每个人的总目标指甲牛皮癣严重程度指数（NAPSI）评分至少3分。钉子随机接受不同的治疗；基线时病灶内注射BoNT-A，在基线和第八周的病灶内TA，每日局部VitD/类固醇应用16周和安慰剂。
■对64个牛皮癣指甲的评估显示，在注射BoNT-A后24周时，总目标NAPSI评分降低了40％（P=.001）。与TA和局部VitD/类固醇相比，BoNT-A显着改善了甲床病变（P=0.038），没有报告的严重不良反应。
■样本量相对较小；COVID-19大流行期间的手部卫生可能会干扰NAPSI评分评估。
■BoNT-A注射液是治疗指甲牛皮癣的一种有前途且有效的疗法，提供持续的疗效持续长达6个月与单次注射。
